公告日期：2026-03-26

InnoCare Pharma Limited

Annual Evaluation Report on 2025 “Quality

Improvement, Efficiency Enhancement and High
Return” Action PlanAnd

2026 “Quality Improvement, Efficiency Enhancement
and High Return”Action Plan

InnoCare Pharma Limited (“InnoCare” or the “Company”) actively and
consistently implements the investor-oriented development philosophy of a listed
company. On 28 March 2025, the Company issued the Annual Evaluation Report on
the 2024 “Quality Improvement, Efficiency Enhancement and High Return” Action
Plan of InnoCare Pharma Limited and 2025 “Quality Improvement, Efficiency
Enhancement and High Return” Action Plan and issued the “Half Year Evaluation
Report on 2025 Quality Improvement, Efficiency Enhancement and High Return
Action Plan of InnoCare Pharma Limited” on 20 August 2025. In 2025, the Company
actively initiated and implemented relevant work based on the “Quality Improvement,
Efficiency Enhancement and High Return” Action Plan and achieved satisfying
results regarding R&D innovation, financial management, corporate governance and
investor relations.

In 2026, the Company will continue to adhere to the core value of “Science
Drives Innovation for the Benefit of Patients”. Based on its own developmental
strategies and operating conditions, the Company has formulated the 2026 “Quality
Improvement, Efficiency Enhancement and High Return”Action Plan.

The implementation details of 2025 “Quality Improvement, Efficiency
Enhancement and High Return” Action Plan and major initiatives under the 2026
“Quality Improvement, Efficiency Enhancement and High Return” Action Plan are as
follow:

I. Focus on the Areas of Oncology and Autoimmune Disease and Enhance Core
Competitiveness

The Company is an innovative biopharmaceutical enterprise driven by its
excellent core self-developed R&D capabilities. It focuses on the areas with extensive
unsatisfied clinical needs such as oncology and autoimmune disease and deve……
[点击查看PDF原文]

提示：本网不保证其真实性和客观性，一切有关该股的有效信息，以交易所的公告为准，敬请投资者注意风险。